Randomised clinical trials are essential to advancing evidence-based medicine and improving human health. But new guidance is needed, which is why we've launched the Good Clinical Trials Collaborative.
Results from well-designed randomised clinical trials tell us the difference between a promising medical intervention and a proven treatment. Their results inform patient care and public health.
Researchers running clinical trials must comply with a complex system of regulations and guidelines that aim to reduce risk, provide clarity and standardise approaches.
However, the over-interpretation of confusing or outdated guidelines has driven up costs through waste, delay and failure, and reduced the availability of proven and affordable treatments for many important health conditions.
New guidance is needed to support a more effective regulatory environment for clinical trials – enabling more informative, ethical and efficient trials to improve patient care.
Launched in June 2020, the Good Clinical Trials Collaborative, supported by Wellcome, the Gates Foundation and the African Academy of Sciences, are reviewing the principles of randomised clinical trials for all types of healthcare interventions, in all settings.
The new guidance will:
To inform the new guidance, we have:
The survey report and draft guidance will be published in June 2021, followed by a public consultation period.
The Collaborative will publish the final guidance in autumn 2021.